Granulocyte and monocyte/macrophage apheresis for the treatment of immune-mediated inflammatory arthropathies: case reports

Article Page

Abstract

Drug therapy of immune-mediated inflammatory arthropathies is not always satisfactory, and there is a risk of adverse events. Granulocyte and monocyte/macrophage apheresis (GMA) is a non-pharmacological therapeutic option that is beneficial and very well tolerated. GMA involves passing blood through a column with cellulose acetate beads to remove increased and activated myeloid lineage cells and improve the cytokine profile. The technique reduces pain and inflammation. We present four clinical reports that illustrate the clinical uses of GMA with the medical device Adacolumn® in patients with different backgrounds and immune-mediated inflammatory arthritis. The results were positive, and no adverse events were reported.

Keywords: disease-modifying anti-rheumatic drugs, leukapheresis, non-steroidal anti-inflammatory agents, pain, psoriatic arthritis, rheumatoid arthritis, tumour necrosis factor inhibitors.

Citation: Carro Martínez AV, Montolio Chiva L, Robustillo Villarino M. Granulocyte and monocyte/macrophage apheresis for the treatment of immune-mediated inflammatory arthropathies: case reports. Drugs Context. 2021;10:2021-8-5. https://doi.org/10.7573/dic.2021-8-5

Contributions: All authors have contributed significantly to the conception, design, or acquisition of data, or analysis and interpretation of data. All authors have participated in drafting, reviewing and/or revising the manuscript and have approved its submission. All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole and have given their approval for this version to be published.

Disclosure and potential conflicts of interest: The authors declare that they have no conflicts of interest relevant to this manuscript. The International Committee of Medical Journal Editors (ICMJE) Potential Conflicts of Interests form for the authors is available for download at: https://www.drugsincontext.com/wp-content/uploads/2021/10/dic.2021-8-5-COI.pdf

Acknowledgements: Writing and editorial assistance was provided by Content Ed Net (Madrid, Spain).

Funding declaration: Writing and editorial assistance was funded by Adacyte.

Copyright: Copyright © 2021 Carro Martínez AV, Montolio Chiva L, Robustillo Villarino M. Published by Drugs in Context under Creative Commons License Deed CC BY NC ND 4.0 which allows anyone to copy, distribute and transmit the article provided it is properly attributed in the manner specified below. No commercial use without permission.

Correct attribution: Copyright © 2021 Carro Martínez AV, Montolio Chiva L, Robustillo Villarino M. https://doi.org/10.7573/dic.2021-8-5. Published by Drugs in Context under Creative Commons License Deed CC BY NC ND 4.0.

Article URL: https://www.drugsincontext.com/granulocyte-and-monocyte-macrophage-apheresis-for-the-treatment-of-immune-mediated-inflammatory-arthropathies:-case-reports

Correspondence: Ana Victoria Carro Martínez, Rheumatology Unit, Hospital Universitario de La Plana, Carretera de Vila-real a Burriana, Km. 0.5, 12540 Vila-real, Castellón, Spain. Email: anavictoriacarro@gmail.com

Provenance: Submitted; externally peer reviewed.

Submitted: 20 August 2021; Accepted: 1 October 2021; Publication date: 5 November 2021.

Drugs in Context is published by BioExcel Publishing Ltd. Registered office: Plaza Building, Lee High Road, London, England, SE13 5PT.

BioExcel Publishing Limited is registered in England Number 10038393. VAT GB 252 7720 07.

For all manuscript and submissions enquiries, contact the Editorial office editorial@drugsincontext.com

For all permissions, rights and reprints, contact David Hughes david.hughes@bioexcelpublishing.com

Download free full text PDF